May. 14 at 7:26 PM
$MGNX focus on pages 8-10 for a minute. Mg 026 is superior to the Daiichi DXd antibody. look at what Merck paid for it. Uhmmmm …….
In October 2023, Merck (known as MSD outside the US and Canada) agreed to pay Daiichi Sankyo an initial
$4 billion upfront for a global development and commercialization collaboration on three of their DXd-based antibody-drug conjugates (ADCs). The total potential value of this deal, including contingent milestones, is up to
$22 billion
